Homoharringtonine suppresses acute myeloid leukemia progression by orchestrating EWSR1 phase separation in an m 6 A‐YTHDF2‐dependent mechanism
iMeta · 2025-12 · 4 (6)
DOI: 10.1002/imt2.70089 ↗Kurz gefasst
Fachartikel in der Zeitschrift iMeta, online erschienen am 30.10.2025. Verfasst von Ting-Ting Liu und 17 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences Peking University Beijing China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Homoharringtonine (HHT) is widely used in combination regimens for acute myeloid leukemia (AML), yet its direct cellular targets remain undefined, limiting precision application. Here, we identified EWS RNA‐binding protein 1 (EWSR1) as the primary target of HHT through chemical proteomics and biophysical validation. HHT bound the RNA recognition motif of EWSR1 with micromolar affinity, inducing an allosteric conformational switch that promoted oligomerization and liquid–liquid phase separation (LLPS). EWSR1 condensates selectively recruited the N 6 ‐methyladenosine (m 6 A) reader YTHDF2, forming cytoplasmic hubs where HHT disrupted YTHDF2–mRNA interactions. This sequestration attenuated m 6 A‐mediated RNA decay, stabilizing key transcripts such as TNFRSF1B and HMOX1 , and thereby impairing AML cell proliferation. Integrated transcriptomics and single‐cell RNA‐seq analyses revealed that EWSR1 was markedly upregulated in AML, particularly in hematopoietic progenitor and myeloid subpopulations, and high EWSR1 expression correlated with poor prognosis and enhanced HHT sensitivity. In vivo, the anti‐leukemic efficacy of HHT was significantly diminished upon EWSR1 knockdown, demonstrating that EWSR1 was required for therapeutic response. Collectively, these findings uncover a phase separation‐centric mechanism by which HHT exerts anti‐AML activity, establish the EWSR1–YTHDF2–m 6 A axis as a critical regulator of leukemia progression, and position EWSR1 as both a functional target and a predictive biomarker for optimizing HHT‐based therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences Peking University Beijing China.
- Institutes of Biomedical Sciences, School of Life Sciences Inner Mongolia University Hohhot China.
- Yunnan Baiyao International Medical Research Center, International Cancer Institute and State Key Laboratory of Molecular Oncology, MOE Frontiers Science Center for Cancer Integrative Omics, School of Basic Medical Scie…
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Pe…
- College of Pharmacy Inner Mongolia Medical University Hohhot China.
- Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences Peking University Beijing China.
ORCID-Profile: Ke-Wu Zeng
Zitieren
APA
Liu, T. T., Chen, L. T., Pei, X. Y., Hu, S. N., Zhuo, F. F., Chen, Z. K., Liu, Y., Wang, J. K., Zhang, J. C., Cao, Q., Li, L., Wang, J., Wei, T. T., Han, B., Tu, P. F., Zhao, X. Y., Xue, R., & Zeng, K. W. (2025). Homoharringtonine suppresses acute myeloid leukemia progression by orchestrating EWSR1 phase separation in an m 6 A‐YTHDF2‐dependent mechanism. iMeta, 4(6). https://doi.org/10.1002/imt2.70089
Vancouver
Liu TT, Chen LT, Pei XY, Hu SN, Zhuo FF, Chen ZK, et al. Homoharringtonine suppresses acute myeloid leukemia progression by orchestrating EWSR1 phase separation in an m 6 A‐YTHDF2‐dependent mechanism. iMeta. 2025;4(6). doi:10.1002/imt2.70089
BibTeX
@article{Liu2025,
author = {Liu, Ting-Ting and Chen, Li-Ting and Pei, Xu-Ying and Hu, Shao-Nan and Zhuo, Fang-Fang and Chen, Ze-Kun and Liu, Yang and Wang, Jing-Kang and Zhang, Ji-Chao and Cao, Qi and Li, Ling and Wang, Jing and Wei, Tian-Tian and Han, Bo and Tu, Peng-Fei and Zhao, Xiang-Yu and Xue, Ruidong and Zeng, Ke-Wu},
title = {Homoharringtonine suppresses acute myeloid leukemia progression by orchestrating EWSR1 phase separation in an m 6 A‐YTHDF2‐dependent mechanism},
journal = {iMeta},
year = {2025},
volume = {4},
number = {6},
doi = {10.1002/imt2.70089}
}
EUVIMED